Opinion | One Exit Won’t Cure the FDA’s Culture

This article highlights ongoing challenges within the FDA's culture that hinder timely and flexible approval processes for critical medical innovations. Addressing these issues is vital for improving patient access to new treatments and fostering a more adaptive regulatory environment in the tech-driven healthcare industry.

• The FDA's strict evidentiary standards often delay access to new treatments.
• Current culture shows resistance to regulatory flexibility intended by Congress.
• Reforming the FDA's mindset is essential for better balancing safety and innovation.